Login / Signup

Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN-6 Trial.

Ahmed A KolkailahIldiko LingvayIdit Dobrecky-MeryAlona AharonovichJens-Peter DavidCecilie HolseSøren RasmussenDarren K McGuire
Published in: Diabetes, obesity & metabolism (2022)
Keyphrases